Frontiers in Clinical Drug Research - CNS and Neurological Disorders

Volume: 1

Indexed in: EBSCO, Scopus.

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is an eBook series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for ...
[view complete introduction]

US $
30

*(Excluding Mailing and Handling)



Advances in Therapies for Multiple Sclerosis

Pp. 38-68 (31)

Naila Makhani and Eluen A. Yeh

Abstract

Several therapeutic agents are currently used as first-line agents in the management of multiple sclerosis (MS) including interferon-beta 1a, interferon-beta 1b, and glatiramer acetate. Currently approved second-line agents include natalizumab, cyclophoshamide, mitoxantrone and the oral agent fingolimod. In addition, there are several emerging therapeutic agents including laquinimod, alemtuzumab, teriflunomide, ocrelizumab, and fumaric acid that are presently being evaluated in clinical trials. While these new treatments have the potential to have a powerful effect on MS disease activity, many also carry significant risks of adverse events or tolerability concerns. With the expanding repertoire of available MS therapies clinicians will have to carefully consider efficacy, safety, and tolerability when engaging with patients to make treatment decisions. In this article, we describe the mechanism of action, efficacy data, and side effect profile of MS therapies with a focus on the newly emerging agents.

Keywords:

Multiple sclerosis, therapy, treatment, immunotherapy, interferon, glatiramer acetate, natalizumab, rituximab, fingolimod, alemtuzumab, ocrelizumab, laquinimod, cyclophosphamide, daclizumab, teriflunamide.

Affiliation:

University of Toronto, Director, Pediatric MS and Demyelinating Disorders Program, Hospital for Sick Children, Department of Neurology, 555 University Avenue, Toronto, ON M5G 1X8, Canada.